Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Liabilities: 2016-2025

Historic Other Non-Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to $1.1 million.

  • Rocket Pharmaceuticals' Other Non-Current Liabilities fell 7.09% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 7.09%. This contributed to the annual value of $1.1 million for FY2024, which is 61.14% down from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Other Non-Current Liabilities is $1.1 million, which was down 0.00% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Other Non-Current Liabilities registered a high of $2.9 million during Q4 2023, and its lowest value of $37,000 during Q3 2022.
  • Its 3-year average for Other Non-Current Liabilities is $1.6 million, with a median of $1.2 million in 2024.
  • In the last 5 years, Rocket Pharmaceuticals' Other Non-Current Liabilities spiked by 4,951.35% in 2023 and then slumped by 61.14% in 2024.
  • Rocket Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $80,000 in 2021, then surged by 3,143.75% to $2.6 million in 2022, then climbed by 13.14% to $2.9 million in 2023, then plummeted by 61.14% to $1.1 million in 2024, then dropped by 7.09% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.